You are here

FDA Approves Flonase Sensimist as OTC Allergy Treatment

The product was previously available by prescription as Veramyst

The FDA has approved Flonase Sensimist Allergy Relief (fluticasone furoate, 27.5-mcg spray, GlaxoSmithKline) as an over-the-counter (OTC) treatment for symptoms associated with seasonal and perennial allergies. Previously available by prescription as Veramyst, Flonase Sensimist is the latest Rx-to-OTC switch from GSK.

Flonase Sensimist is indicated for the treatment of symptoms associated with seasonal and perennial allergic rhinitis, including sneezing, runny nose, itchy nose, congestion, and itchy, watery eyes, in adults and children 2 years of age and older. The indication for itchy, watery eyes is for individuals 12 years of age and older.

Fluticasone furoate acts on multiple inflammatory substances (histamine, prostaglandins, cytokines, tryptases, chemokines, and leukotrienes). The exact number and precise mechanism are unknown.

Flonase Sensimist will be nationally available in early 2017.

Source: PR Newswire; August 3, 2016.

Recent Headlines

Medical Device Enables Nerve Stimulation During Sleep
May Offer Improved Safety Profile for Pediatric Patients
Hope for Sufferers With Post-Treatment Lyme Disease Syndrome
KardiaMobile Receives Two More Clearances for Arrhythmia Detection
Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
Current, Sole Therapy Not Always Successful/Suitable